Lung carcinoma is a major cause of cancer death, especially non-small cell lung cancer (NSCLC) has the worse prognosis, with survival rate over 5 years below 15%.

Unfortunately, there is still a lack of efficient treatments for several patients despite the large number of recently approved therapeutic classes, from chemotherapy to immunotherapy. The objective of the present project is to develop a preclinical/translational model that recapitulates the heterogeneity of tumors in order to better select treatment options, and to support the research for novel drugs with improved properties. We here propose an in vitro 3D model derived from patient’s tumor biopsies, that reconstitutes the tumor vasculization and the microenvironment directly from patients’ biopsies. This advanced assay was designed to match the criteria of drug assessment and screening, and in the longer term to promote the access to personalized medicine for patients with NSCLC.

MATERIAL & METHODS

Methods

Human specimens

Biopsies of lung cancer and healthy tissues were obtained by surgery. Patients’ informed consents were managed by the CRB (Centre de Ressources Biologiques des Hôpitaux Universitaires de Strasbourg). Samples were confirmed as tumoral or normal tissues following anatomopathological analysis.

Tissue preparation and culture of PDOs

Human samples were washed in PBS and enzymatic digestion was performed at 37°C for 1h with intermittent agitation. After incubation, the reaction media containing samples was transferred to a Falcon tube through 70µm cell strainers. The strained cells were centrifuged and the pellet was resuspended in 5ml of DMEM-F12 (Lonza). The cell suspension was then seeded for a final volume per drop of 40µl in AkuraPLUS™ hanging drop system (96 wells). PDOs formed after 5 days of incubation at 37°C.

Histology and imaging

Healthy and tumoral PDOs were fixed in 4% paraformaldehyde (PFA). They were given to anatomical pathologists to perform IHC and standard H&E staining.

IF

Healthy and tumoral PDOs were harvested and placed in molds with optical coherence tomography (OCT) then frozen. The obtained blocks were sectioned, fixed in 4% PFA, permeated and blocked with 0.3% Triton X-100/1% BSA/PBS for 30min. They were incubated with primary antibodies overnight at 4°C. Primary antibodies were detected by secondary antibodies, incubated for 1h at RT. Nuclei were stained with DAPI (1:2000 dilutions, D9542, Sigma) for 5min. Imaging was performed on a Leica DM4000 B microscope.

Drug screening

PDOs cultured in in spheroid plates over 5 days were harvested in a ULA-plate. PDOs were then tested with 7 concentrations of taxol and DMSO controls for 2 controls. After 2 days, the organsoids were transferred in a 96 well plate and the medium was changed to 100µl of fresh PDO media and 200µl Cell Titer-Glo (Promega). The plates were agitated 10min at RT prior to luminescence reading.

REFERENCES


RESULTS & DISCUSSION

Study Objectives

• To validate the patients’ derived organoids (PDOs)
• To establish a multicellular organoid
• To perform drug screening and see the correlation between preclinical responses and clinical responses
• To develop a microfluidic device

Results

A Tumoral tissue PDO (D4)

B Healthy tissue Healthy PDO (D4)

Discussion

A limit often described in cancer 3D models is the lack of tumor microenvironment, and particularly of non-immune cells, such as stromal cells and immune cells. With the new era of immune checkpoint inhibitors, a co-culture system with immune-infiltrating cells would be better to study their efficacy. PDOs associated in a microfluidic device may be more accurate to assess drugs in different modes of administration because of their physiological relevance with the primary tumor.

CONCLUSION

The challenge is to develop more relevant in vitro models, recapitulating histological and genetic features of lung cancer taking into consideration the tumor microenvironment and its various cells component. The vascular and immune components must now be included in the PDO system, as they largely influence tumor growth and response to drugs. This will be of high importance in the perspective of personalized treatment and combination treatment. Lung cancer has been shown to be highly immunogenic, and is thus responsive to checkpoint blockade therapy. Oncolytic virotherapy is an emergent therapy for the treatment of cancer that could advantageously combine with existing treatments. New oncolytic virus candidates will be evaluated on this innovative device.